ArticleBiochemistry and biophysics reports2026
IGSF9 promotes immunotherapy resistance in colon cancer by orchestrating an immunosuppressive tumor microenvironment and enables combinatorial targeting strategies.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colon cancer (CC), a significant global health burden with high incidence and mortality, is often accompanied by an immunosuppressive tumor microenvironment (TME) that limits the efficacy of immunotherapy. Immunoglobulin superfamily member 9 (IGSF9), a cell surface protein involved in cell adhesion and signaling, has been shown to promote tumor progression and regulate TME in other cancers, but its role in CC remains poorly understood. This study integrated multi-omics analyses, single-cell sequencing, and preclinical models to explore IGSF9's function in CC and its correlation with immunotherapy resistance. The results showed that IGSF9 was significantly upregulated in CC tumors, positively correlated with advanced tumor stages and poor prognosis such as reduced overall survival in colon adenocarcinoma (COAD). High IGSF9 expression was correlated with an immunosuppressive TME characterized by increased infiltration of regulatory T cells (Tregs), cancer-associated fibroblasts (CAFs), and reduced immune cell infiltration; it was also linked to lower tumor mutational burden (TMB) and microsatellite instability (MSI), predicting poor response to anti-PD-1 immunotherapy in clinical datasets. Single-cell and spatial transcriptomics revealed that IGSF9 was predominantly expressed in malignant epithelial cells, correlated with epithelial-mesenchymal transition (EMT) pathways. Drug sensitivity analysis identified Doramapimod, a MAPK inhibitor, which combined with anti-PD-1 therapy significantly enhanced tumor regression in mouse models by reducing Treg infiltration. In conclusion, this study establishes IGSF9 as a prognostic and predictive biomarker for immunotherapy resistance in CC and suggests that targeting IGSF9-associated KRAS/MAPK pathways with Doramapimod may offer a novel combination strategy to overcome TME-mediated resistance, warranting further clinical investigation for personalized CC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.